Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 2015. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in interests in GSK Ordinary shares.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific executive compensation transaction and does not contain consolidated financial statements.
Material Changes
The filing details a transaction on May 8, 2015, involving Executive Director S. Dingemans under the GSK Deferred Annual Bonus Plan:
- Exercise of a nil-priced option over 34,220 shares and 4,620 shares granted on March 9, 2012.
- Both tranches vested on March 9, 2015.
- GSK delivered the net-of-tax value in shares, totaling 20,585 shares.
- The fair market value of an Ordinary Share at the point of exercise was £14.72.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of a director's share transaction.
Key Facts for Investor Verification
- Transaction Date: May 8, 2015.
- Executive Involved: S. Dingemans.
- Shares Received: 20,585 shares (net of tax).
- Share Price: £14.72 per share at exercise.
- Notification Date: May 11, 2015.